Reck-Notch1 Signaling Mediates miR-221/222 Regulation of Lung Cancer Stem Cells in NSCLC

Yuefan Guo, Guangxue Wang, Zhongrui Wang, Xin Ding, Qian Lü, Ya Li, Zhen Ren, Pengfei Liu, Wenjing Ma, Danni Li, Yuan Li, Qian Zhao, Jinhui Lü, Qinchuan Li, Qinhong Wang, Zuoren YuFrontiers in Cell and Developmental Biology 2021 · DOI

Abstract

Cancer stem cells (CSCs) contribute to the cancer initiation, metastasis and drug resistance in non-small cell lung cancer (NSCLC). Herein, we identified a miR-221/222 cluster as a novel regulator of CSCs in NSCLC. Targeted overexpression or knockdown of miR-221/222 in NSCLC cells revealed the essential roles of miR-221/222 in regulation of lung cancer cell proliferation, mammosphere formation, subpopulation of CD133<sup>+</sup> CSCs and the expression of stemness genes including OCT4, NANOG and h-TERT. The in vivo animal study showed that overexpression of miR-221/222 significantly enhanced the capacity of lung cancer cells to develop tumor and grow faster, indicating the importance of miR-221/222 in tumorigenesis and tumor growth. Mechanistically, Reck was found to be a key direct target gene of miR-221/222 in NSCLC. Overexpression of miR-221/222 significantly suppressed Reck expression, activated Notch1 signaling and increased the level of NICD. As an activated form of Notch1, NICD leads to enhanced stemness in NSCLC cells. In addition, knockdown of Reck by siRNA not only mimicked miR-221/222 effects, but also demonstrated involvement of Reck in the miR-221/222-induced activation of Notch1 signaling, verifying the essential roles of the miR-221/222-Reck-Notch1 axis in regulating stemness of NSCLC cells. These findings uncover a novel mechanism by which lung CSCs are significantly manipulated by miR-221/222, and provide a potential therapeutic target for the treatment of NSCLC.

Introduction

Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases and remains a leading cause of cancer-related mortality due to high rates of recurrence and chemoresistance. These aggressive traits are largely driven by Cancer Stem Cells (CSCs), a small subpopulation within the tumor capable of self-renewal and initiating new tumors. Identifying the molecular "circuitry" that maintains these cells in a stem-like state is critical for developing effective therapies. This study investigates the role of the miR-221/222 cluster in regulating lung CSCs through the Reck-Notch1 signaling pathway.

Methods

The researchers employed a multi-tiered experimental approach to map the miR-221/222 regulatory pathway:

  • Screening & Isolation: CD133+ CSCs were isolated from A549 and H1299 NSCLC cell lines using Fluorescence-Activated Cell Sorting (FACS). miRNA expression profiles were then compared between CD133+ and CD133- populations.
  • Functional Assays: Gain-of-function (overexpression) and loss-of-function (knockdown) experiments assessed cell proliferation, colony formation, and mammosphere formation—a gold-standard test for stemness.
  • In Vivo Validation: Xenograft mouse models were used to observe the impact of miR-221/222 on real-world tumor initiation and growth rates.
  • Mechanistic Mapping: Bioinformatics tools predicted target genes, which were validated using Luciferase Reporter Assays to prove direct binding to the Reck 3'UTR. Western Blotting tracked the downstream activation of the Notch1 signaling pathway.

Key Results

The study identified miR-221 and miR-222 as highly enriched in lung CSCs. Expression levels of these miRNAs were significantly higher in NSCLC cell lines compared to normal bronchial epithelial cells (BEAS-2B) and correlated positively with clinical tumor stage, with higher expression observed in Stage II/III versus Stage I tumors.

miR-221/222 expression profiling and clinical correlation in NSCLC.

Functional assays demonstrated that miR-221/222 overexpression increased the CD133+ subpopulation and upregulated stemness markers such as OCT4 and NANOG. Mechanistically, miR-221/222 directly targets and suppresses Reck, a tumor suppressor that normally inhibits Notch1 activation. Suppression of Reck leads to increased levels of the Notch1 Intracellular Domain (NICD), which translocates to the nucleus to drive the stemness program. Knockdown of Reck using siRNA successfully mimicked the effects of miR-221/222 overexpression, confirming the miR-221/222-Reck-Notch1 axis as a primary driver of CSC maintenance.

Discussion and Limitations

This research highlights the miR-221/222 cluster as a master regulator of stemness in NSCLC. By suppressing the tumor suppressor Reck, these miRNAs activate Notch1 signaling, thereby expanding the CSC pool and promoting tumor growth. While the study provides a clear mechanistic pathway, some limitations remain. The exact biochemical interactions between Reck and Notch1 proteases like ADAM10 require further exploration. Additionally, while miR-221/222 is a promising therapeutic target, the challenge of effective miRNA inhibitor delivery to lung tumors in patients remains a significant hurdle for clinical translation. Future work should also investigate if this pathway is universal across other lung CSC subtypes beyond CD133+ cells.

Summary updated

Abstract

Cancer stem cells (CSCs) contribute to the cancer initiation, metastasis and drug resistance in non-small cell lung cancer (NSCLC). Herein, we identified a miR-221/222 cluster as a novel regulator of CSCs in NSCLC. Targeted overexpression or knockdown of miR-221/222 in NSCLC cells revealed the essential roles of miR-221/222 in regulation of lung cancer cell proliferation, mammosphere formation, subpopulation of CD133<sup>+</sup> CSCs and the expression of stemness genes including OCT4, NANOG and h-TERT. The <i>in vivo</i> animal study showed that overexpression of miR-221/222 significantly enhanced the capacity of lung cancer cells to develop tumor and grow faster, indicating the importance of miR-221/222 in tumorigenesis and tumor growth. Mechanistically, Reck was found to be a key direct target gene of miR-221/222 in NSCLC. Overexpression of miR-221/222 significantly suppressed Reck expression, activated Notch1 signaling and increased the level of NICD. As an activated form of Notch1, NICD leads to enhanced stemness in NSCLC cells. In addition, knockdown of Reck by siRNA not only mimicked miR-221/222 effects, but also demonstrated involvement of Reck in the miR-221/222-induced activation of Notch1 signaling, verifying the essential roles of the miR-221/222-Reck-Notch1 axis in regulating stemness of NSCLC cells. These findings uncover a novel mechanism by which lung CSCs are significantly manipulated by miR-221/222, and provide a potential therapeutic target for the treatment of NSCLC.
BibTeX
@inproceedings{guo2021reck,
  author = {Yuefan Guo and Guangxue Wang and Zhongrui Wang and Xin Ding and Qian Lü and Ya Li and Zhen Ren and Pengfei Liu and Wenjing Ma and Danni Li and Yuan Li and Qian Zhao and Jinhui Lü and Qinchuan Li and Qinhong Wang and Zuoren Yu},
  title = {{Reck-Notch1 Signaling Mediates miR-221/222 Regulation of Lung Cancer Stem Cells in NSCLC}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.663279},
}
Figure